ABIVAX Société Anonyme (AAVXF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Peers in Healthcare
ABIVAX Société Anonyme has no peer companies in this window.
Recent press releases
April 2026
Abivax Announces Annual General Meeting for May 11, 2026
# 📜 What This Document Is 📄 This is a Form 6-K, which is a standardized report filed with the U.S. Securities and Exchange Commission (SEC). Since Abivax S.A. is a foreign company, this filing allows them to update U.S. investors and regulators on material events that happen back in France. Gener
SEC filings
All filings →Insider trades
All insider trades →ABIVAX Société Anonyme has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at ABIVAX Société Anonyme
All people →No officers or directors have been indexed for ABIVAX Société Anonyme.